Quantcast
Home > Quotes > LGND
LGND

Ligand Pharmaceuticals Incorporated Common Stock (LGND) Quote & Summary Data

$148.54
*  
5.92
3.83%
Get LGND Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading LGND now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    LGND Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 154.24 / $ 147.5561
Share Volume
478,936
50 Day Avg. Daily Volume
729,276
Previous Close
$ 154.46
52 Week High / Low
$ 278.62 / $ 126.50
Market Cap
3,157,028,460
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
478,936
50 Day Avg. Daily Volume:
729,276

P/E Ratio

P/E Ratio:
20.38
Forward P/E (1y):
25.13
Earnings Per Share (EPS):
$ 7.29

Trading Range

The current last sale of $148.54 is 17.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 154.24 $ 278.62
 Low: $ 147.5561 $ 126.50

ETFs with LGND as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.03% Virtus LifeSci Biotech Products ETF (BBP) -6.76 (-15.68%)
0% ProShares Ultra SmallCap600 (SAA) -17.48 (-15.01%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. Over our more than 30 year history, we have employed research technologies such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward securing prescription drug approvals. We currently have partnerships and license agreements with over 95 pharmaceutical and biotechnology companies, and over 165 different programs under license with us are currently in various stages of commercialization and development. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.  ... More ...  


Risk Grade

Where does LGND fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 153.85
Open Date:
Nov. 19, 2018
Close Price:
$ 148.54
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x